← All Prime Medicine, INC filings

Prime Medicine, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PRME
Prime Medicine, INC
10-K: Prime Medicine Faces Going Concern Doubt Amidst Losses, Key Pipeline Shifts
Prime Medicine reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing its gene editing pipeline and securing new collaborations.
NASDAQ
PRME
Prime Medicine, INC
10-K: Prime Medicine Reports Full Year 2024 Results, Highlights Progress in Gene Editing Therapies
Prime Medicine's 2024 10-K filing reveals a strategic focus on hematology, immunology, oncology, liver, and lung programs, alongside ongoing efforts in Prime Editing technology and key collaborations.
NASDAQ
PRME
Prime Medicine, INC
10-K: Prime Medicine Outlines Gene Editing Strategy in Annual Report, Eyes First Clinical Trial
Prime Medicine's annual report details its progress in developing Prime Editing technology for various diseases, with plans to submit an IND for its lead candidate in the first half of 2024.